Inhaler monitoring company Adherium has named former Vectura CEO James Ward-Lilley as a director and Chairman of the Board after the recent death of Thomas Lynch, who had been Chairman since 2016. The company also promoted Mike Motion from Chief Commercial Officer, a position he had held since November 2019, to Chief Operating Officer.
Prior to joining Vectura as CEO in 2015, Ward-Lilley held a number of roles at AstraZeneca, including VP Respiratory, Autoimmune, and Inflammation. At AstraZeneca, he was involved with the acquisitions of Pearl Therapeutics and Almirall’s respiratory business. In June 2019, he left Vectura and was succeeded as CEO at that company by Will Downie.
Ward-Lilley said, “I am pleased to be joining the Adherium Board and look forward to working with the whole team, executives and Board to ensure the business delivers on its untapped potential for patients and providers and in so doing creates significant shareholder value. This is an exciting time for Adherium with reimbursement for remote patient monitoring now in place in the US, a new high quality management team implementing a focused, market relevant, provider value driven strategy and a clear development roadmap to re-establish Adherium’s market leadership in inhaled medication device coverage including physiological data reporting. Following the refinancing of the business 2020 is set to be a transformational year for Adherium. Having worked as a consultant in the business for the last few months I am pleased to be able to report a step change in the progress being made in the business and look forward to a very promising series of upcoming news flow, including US commercial progress, in the near term.”
Adherium launched its Hailie inhaler sensor in the US in August 2018. In November 2019, the company announced that Trudell Medical Limited, parent company of respiratory device companies Trudell Medical International, Monaghan Medical, and NasoNeb, had made a $1.1 million strategic investment in Adherium.
Read the Adherium press release.
